Characterization of the gut microbiota in diabetes mellitus II patients with adequate and inadequate metabolic control

Hamasaki-Matos, Angie Joyce; Cóndor-Marín, Katherine Marlene; Aquino-Ortega, Ronald; Carrillo-Ng, Hugo; Ugarte-Gil, César; Silva-Caso, Wilmer; Aguilar-Luis, Miguel Ángel; Valle-Mendoza, Juana del

doi:10.1186/s13104-021-05655-z

Cited by 4 publications

(2 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…All of the patients were enrolled in an education program on diabetes at our hospital, and they followed the guidelines for a diabetic diet. We excluded patients who used antibiotics within 1 month prior to enrollment, the same as previous studies [ 27 , 28 , 29 ]. In addition, patients with inflammatory bowel disease, those who had received gastrointestinal tract surgery, and those with cancer who had undergone chemotherapy within 1 year prior to enrollment were also excluded.…”

Section: Methodsmentioning

confidence: 99%

Gut Microbiota and Subclinical Cardiovascular Disease in Patients with Type 2 Diabetes Mellitus

Tsai

Hung

et al. 2021

Nutrients

View full text Add to dashboard Cite

Type 2 diabetes (T2D) is associated with an increased risk of cardiovascular disease (CVD). The gut microbiota may contribute to the onset and progression of T2D and CVD. The aim of this study was to evaluate the relationship between the gut microbiota and subclinical CVD in T2D patients. This cross-sectional study used echocardiographic data to evaluate the cardiac structure and function in T2D patients. We used a quantitative polymerase chain reaction to measure the abundances of targeted fecal bacterial species that have been associated with T2D, including Bacteroidetes, Firmicutes, Clostridium leptum group, Faecalibacterium prausnitzii, Bacteroides, Bifidobacterium, Akkermansia muciniphila, and Escherichia coli. A total of 155 subjects were enrolled (mean age 62.9 ± 10.1 years; 57.4% male and 42.6% female). Phyla Bacteroidetes and Firmicutes and genera Bacteroides were positively correlated with the left ventricular ejection fraction. Low levels of phylum Firmicutes were associated with an increased risk of left ventricular hypertrophy. High levels of both phylum Bacteroidetes and genera Bacteroides were negatively associated with diastolic dysfunction. A high phylum Firmicutes/Bacteroidetes (F/B) ratio and low level of genera Bacteroides were correlated with an increased left atrial diameter. Phyla Firmicutes and Bacteroidetes, the F/B ratio, and the genera Bacteroides were associated with variations in the cardiac structure and systolic and diastolic dysfunction in T2D patients. These findings suggest that changes in the gut microbiome may be the potential marker of the development of subclinical CVD in T2D patients.

show abstract

Section: Methodsmentioning

confidence: 99%

Gut Microbiota and Subclinical Cardiovascular Disease in Patients with Type 2 Diabetes Mellitus

Tsai

Hung

et al. 2021

Nutrients

View full text Add to dashboard Cite

show abstract

“…In a study involving 26 patients with type 2 diabetes, Prevotella , Firmicutes , Proteobacteria and Bacteroidetes were observed in increased abundance [ 36 ]. Xue Zhao and his collaborators compared the gut microbiota composition of people with type 2 diabetes mellitus and people with normal glycemic control in their study.…”

Section: Gut Microbiota and Metabolic Diseasesmentioning

confidence: 99%

The Biotics Family: Current Knowledge and Future Perspectives in Metabolic Diseases

Palade¹,

Vulpoi

et al. 2022

Life

View full text Add to dashboard Cite

Globally, metabolic diseases such as obesity, type 2 diabetes mellitus and non-alcoholic fatty liver disease pose a major public health threat. Many studies have confirmed the causal relationship between risk factors and the etiopathogenesis of these diseases. Despite this, traditional therapeutic management methods such as physical education and diet have proven insufficient. Recently, researchers have focused on other potential pathways for explaining the pathophysiological variability of metabolic diseases, such as the involvement of the intestinal microbiota. An understanding of the relationship between the microbiome and metabolic diseases is a first step towards developing future therapeutic strategies. Currently, much attention is given to the use of biotics family members such as prebiotics (lactolose, soy oligosaccharides, galactooligosaccharides, xylooligosaccharides or inulin) and probiotics (genera Lactobacillus, Bifidobacterium, Lactococcus, Streptococcus or Enterococcus). They can be used both separately and together as synbiotics. Due to their direct influence on the composition of the intestinal microbiota, they have shown favorable results in the evolution of metabolic diseases. The expansion of the research area in the biotics family has led to the discovery of new members, like postbiotics. In the age of personalized medicine, their use as therapeutic options is of great interest to our study.

show abstract

Targeting gut microbiota in type 2 diabetes mellitus: Potential roles of dietary flavonoids

Han

Luo

et al. 2022

Food Bioscience

View full text Add to dashboard Cite

Characterization of the gut microbiota in diabetes mellitus II patients with adequate and inadequate metabolic control

Cited by 4 publications

References 20 publications

Gut Microbiota and Subclinical Cardiovascular Disease in Patients with Type 2 Diabetes Mellitus

Gut Microbiota and Subclinical Cardiovascular Disease in Patients with Type 2 Diabetes Mellitus

The Biotics Family: Current Knowledge and Future Perspectives in Metabolic Diseases

Targeting gut microbiota in type 2 diabetes mellitus: Potential roles of dietary flavonoids

Contact Info

Product

Resources

About